Qiagen shares rise 1.53% premarket after FDA clearance of higher-throughput QIAstat-Dx Rise system.

Qiagen N.V. rose 1.53% in premarket trading, with the company announcing the launch of QIAstat-Dx Rise, a higher-throughput version of its automated syndromic testing system. This new system, cleared by the U.S. FDA, is designed to meet the needs of hospitals and reference laboratories seeking highly automated syndromic testing with automated loading and unloading of cartridges, access to priority handling of urgent samples, and only a minimum of hands-on time. This clearance marks QIAGEN's third FDA-cleared QIAstat-Dx product in 2025, and builds on a growing portfolio of six panels.